BioNTech Rewrites Its Roche Pact and Buys an FDA Fast Lane While Tightening 2026 Guidance
Published on 11/21/2026 at 09:40 | Editorial boerse-global.deBioNTech has been working two timelines at once: the revenue it books this year and the regulatory runway for a cancer drug still in late-stage development. The Mainz-based biotech moved on both fronts in recent weeks, striking a $205 million deal for an FDA priority review voucher and restructuring its cost-sharing arrangement with Roche and Genentech — a switch to a royalty model that takes effect January 1, 2027, at which point the two partners will generally shoulder the program's future research and development costs.
The voucher purchase, agreed with Scholar Rock, hands BioNTech an expedited FDA review ticket it intends to attach to a future marketing application from its advanced oncology pipeline. Cash consideration is set at $205 million, and the transaction remains subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino process.
Third-Quarter Numbers and a Narrowed Outlook
The company's third-quarter 2026 report, released in early November, showed revenue of EUR 1.29 billion and net profit of EUR 184.5 million. Alongside those figures, BioNTech refined its full-year 2026 revenue guidance to the upper end of its prior range, now projecting EUR 1.7 billion to EUR 1.9 billion. Cash, cash equivalents and securities investments stood at EUR 16.2 billion at the close of the quarter.
Should investors sell immediately? Or is it worth buying BioNTech?
Analysts have been adjusting their models in response. Citi's Geoff Meacham reaffirmed his rating on November 11. At J.P. Morgan, Jessica Fye kept a "Neutral" stance on Thursday while nudging her price target to $93 from $92.
Shares slipped 0.5% in the prior session, closing at EUR 73.80.
Ad
BioNTech Stock: New Analysis - 21 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
